Respiratory viral infections in the immunocompromised

Michael G. Ison*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Purpose of reviewDuring much of the COVID-19 pandemic, respiratory viruses other than SARS-CoV-2 did not infect immunocompromised patients. As mitigation strategies lighten, there has been a rapid resurgence of respiratory viruses globally. This review will summarize our current options for the management of the common respiratory viruses in transplant recipients.Recent findingsExpansion of the availability and increased utilization of multiplex molecular assays have allowed the recognition of the scope of respiratory virus infections in the transplant populations. New antivirals for influenza, respiratory syncytial virus (RSV), parainfluenza virus (PIV) and adenovirus show promise to improve outcomes of these important infections.SummarySeveral new antiviral agents, including combination therapy of oseltamivir as well as baloxavir for influenza, fusion and nucleoprotein inhibitors for RSV, DAS181 for PIV and brincidofovir for adenovirus, hold promise to speed clearance of the virus, improve clinical outcomes and reduce the risk of resistance emergence.

Original languageEnglish (US)
Pages (from-to)205-210
Number of pages6
JournalCurrent opinion in pulmonary medicine
Issue number3
StatePublished - May 1 2022


  • adenovirus
  • influenza
  • parainfluenza virus
  • respiratory syncytial virus

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Respiratory viral infections in the immunocompromised'. Together they form a unique fingerprint.

Cite this